Drug Profile
Transforming growth factor-alpha
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Antiulcers; Antivirals; Growth factors; Transforming growth factors
- Mechanism of Action Transforming growth factor alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Oct 2002 Discontinued - Preclinical for Cancer in Italy (unspecified route)
- 30 Jul 1998 No-Development-Reported for Cancer in Italy (Unknown route)
- 12 Apr 1995 Preclinical development for Cancer in Italy (Unknown route)